News FocusNeuroscience

Fetal Cells Again?

Science  16 Oct 2009:
Vol. 326, Issue 5951, pp. 358-359
DOI: 10.1126/science.326_358

You are currently viewing the summary.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


Summary

As lab research on converting human embryonic stem (hES) cells and induced pluripotent stem (iPS) cells into dopamine-producing neurons proceeds apace, there's growing doubt in some quarters about whether cell transplants will ever show a clear benefit for Parkinson's disease beyond what can be achieved by existing therapies. And researchers are increasingly realizing that there's much more to Parkinson's than a dopamine shortage. The debate about cell therapy for Parkinson's may soon become more intense as scientists in Europe, in collaboration with colleagues in North America, are in final negotiations for a large European Commission grant to conduct a new fetal cell transplant trial. The trial will refine clinical methods and be a "steppingstone" to therapies with cells derived from iPS or hES cells, says the principal investigator. Yet news of the plans dismays some who think it's a step backward.